Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 8/20 | 0.53 |
| ▸ | PPARA | Q07869 | 7/20 | 0.53 |
| ▸ | PPARG | P37231 | 6/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1553524 | 0.85 | MAPT (0.46) | PPARDPPARAPPARGMAPTFFAR1 | |
| SCHEMBL3540426 | 0.84 | MAPT (0.43) | PPARDPPARAPPARGMAPTFFAR1 | |
| SCHEMBL14015121 | 0.83 | KDM4E (0.53) | PPARDPPARAPPARGMAPTFFAR1 | |
| SCHEMBL4479582 | 0.83 | PPARD (0.56) | PPARDPPARAPPARGMAPTFFAR1 | |
| SCHEMBL1553173 | 0.83 | MAPT (0.45) | PPARDPPARAPPARGMAPTFFAR1 | |
| SCHEMBL5023897 | 0.80 | PPARD (0.75) | PPARDPPARAPPARGMAPTFFAR1 | |
| SCHEMBL3542677 | 0.80 | CTSS (0.41) | PPARDPPARAPPARGMAPTFFAR1 | |
| SCHEMBL27651073 | 0.79 | MAPT (0.43) | PPARDPPARAPPARGMAPTKDM4E | |
| SCHEMBL28762224 | 0.78 | MAPT (0.47) | PPARDPPARAPPARGMAPTFFAR1 | |
| SCHEMBL1553829 | 0.78 | MAPT (0.56) | PPARDPPARAPPARGMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709509-B2 | Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-7709509-B2 | Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-7709509-B2 | Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| CN-100582104-C | Oxadiazolone derivatives as PPAR delta agonists | SANOFI AVENTIS DEUTSCHLAND | 2010-01-20 | — | — | CN | disclosed |
| EP-2083006-A1 | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2009-07-29 | — | — | EP | disclosed |
| EP-2083006-A1 | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2009-07-29 | — | — | EP | disclosed |
| CN-100516065-C | 1,3, 4-oxadiazol-2-ones as PPAR-Δ modulators | AVENTIS PHARMA INC (US) | 2009-07-22 | — | — | CN | disclosed |
| EP-1740583-B1 | OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-01 | — | — | EP | disclosed |
| EP-1740583-B1 | OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-07-01 | — | — | EP | disclosed |
| US-20080262052-A1 | METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080255212-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255212-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| CN-101018790-A | 7-azaindoles and their use as PPAR agonists | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-08-15 | — | — | CN | disclosed |
| US-20070179191-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-02 | — | — | US | disclosed |
| US-20070179191-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-02 | — | — | US | disclosed |
| US-20070179191-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-02 | — | — | US | disclosed |
| CN-1938300-A | Oxadiazolone derivatives as PPAR delta agonists | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-03-28 | — | — | CN | disclosed |
| CN-1938305-A | 1,3,4-oxadiazol-2-ones as ppar delta modulators and their use thereof | SANOFI AVENTIS DEUTSCHLAND (US) | 2007-03-28 | — | — | CN | disclosed |
| EP-1740583-A1 | OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005097786-A1 | OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179191-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PPAR DELTA AGONISTS | PPARD, PPARA, PPARG | PPARD 1/4885PPARA 2/4885PPARG 3/4885 |
| US-20080255212-A1 | OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | PPARD, PPARG, PPARA | PPARD 1/4885PPARA 3/4885PPARG 2/4885 |
| US-20080262052-A1 | METHODS FOR THE TREATMENT OF METABOLIC AND GLUCOSE UTILIZATION DISORDERS THROUGH THE ADMINISTRATION OF OXADIAZOLONES AND DERIVATIVES THEREOF AS PEROXISOME PROLIFERATOR - ACTIVATED RECEPTOR (PPAR) DELTA AGONISTS | PPARD, PPARG, PPARA | PPARD 1/4885PPARA 3/4885PPARG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.